We are live on
!
Find out more
Neurocrine Biosciences
NBIX
NBIX
225 hedge funds and large institutions have $3.27B invested in Neurocrine Biosciences in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 97 increasing their positions, 75 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
97.13% more ownership
Funds ownership: 0% → 97.13% (+97%)
29% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 75
6% less call options, than puts
Call options by funds: $23.6M | Put options by funds: $25.1M
8% less funds holding
Funds holding: 244 → 225 (-19)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
24% less capital invested
Capital invested by funds: $4.32B → $3.27B (-$1.05B)
37% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 41
Holders
225
Holders Change
-19
Holders Change %
-7.79%
% of All Funds
5.63%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.15%
New
26
Increased
97
Reduced
75
Closed
41
Calls
$23.6M
Puts
$25.1M
Net Calls
-$1.48M
Net Calls Change
-$32.7M
Top Buyers
| 1 |
Millennium Management
New York
|
+$55.6M |
| 2 |
HM
HealthCor Management
New York
|
+$44.8M |
| 3 |
PA
Perceptive Advisors
New York
|
+$38M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$18M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$16.1M |
